Drugs / BB3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01539590 | Jul 2012 → Jul 2013 | myocardial infarction | Angion Biomedica Corp | Terminated | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01561599 Comparator | Aug 2011 → Feb 2016 | — | Angion Biomedica Corp | Unknown | No outcome recorded |
| Phase 2 | NCT01286727 Comparator | Feb 2010 → Jan 2015 | — | Angion Biomedica Corp | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01286727 ↗ |
| Modality | Small molecule | “a small molecule mimetic of hepatocyte growth factor/scatter factor (HGF/SF)” NCT01539590 ↗ |
| Route | Intravenous | “intravenous drug” NCT01286727 ↗ |